Anteris Technologies’ IPO has made waves, raising $125 million at $50 per share and being oversubscribed by nine times. The funds will support the global commercialization of its innovative DurAVR transcatheter heart valve, targeting the booming structural heart device market, which grows at a 12% CAGR. With institutional backing from firms like Sequoia and BlackRock, analysts predict a strong debut share price of $55-$65. This positions Anteris as a potential disruptor in the heart valve industry. Read more on Minichart.
Anteris Technologies’ IPO has made waves, raising $125 million...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$6.03 |
Change
0.010(0.17%) |
Mkt cap ! $93.45M | |||
| Open | High | Low | Value | Volume |
| $6.00 | $6.16 | $5.80 | $52.24K | 8.792K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 857 | $5.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.45 | 1000 | 1 |
View Market Depth
| Last trade - 15.36pm 20/06/2025 (20 minute delay) ? |
| AVR (ASX) Chart |